Literature DB >> 21704230

TP53 mutations in human cancer: database reassessment and prospects for the next decade.

Thierry Soussi1.   

Abstract

TP53 mutations are the most frequent genetic alterations found in human cancer. For more than 20 years, TP53 mutation databases have collected over 30,000 somatic mutations from various types of cancer. Analyses of these mutations have led to many types of studies and have improved our knowledge about the TP53 protein and its function. The recent advances in sequencing methodologies and the various cancer genome sequencing projects will lead to a profound shift in database curation and data management. In this paper, we will review the current status of the TP53 mutation database, its application to various fields of research, and how data quality and curation can be improved. We will also discuss how the genetic data will be stored and handled in the future and the consequences for database management.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704230     DOI: 10.1016/B978-0-12-386469-7.00005-0

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  33 in total

1.  The CRM1 nuclear export protein in normal development and disease.

Authors:  Kevin T Nguyen; Michael P Holloway; Rachel A Altura
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

2.  Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.

Authors:  Weili Wang; Songlei Guan; Shilong Sun; Yonglong Jin; Kuang-Hui Lee; Yubing Chen; Jun Wei
Journal:  Tumour Biol       Date:  2014-01-23

3.  Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells.

Authors:  Fengchun Ye; Ali Abdul Lattif; Jianping Xie; Aaron Weinberg; Shoujiang Gao
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

4.  The mutational status of p53 can influence its recognition by human T-cells.

Authors:  Katerina Shamalov; Shlomo N Levy; Miryam Horovitz-Fried; Cyrille J Cohen
Journal:  Oncoimmunology       Date:  2017-01-31       Impact factor: 8.110

5.  Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors.

Authors:  Karolina Edlund; Ola Larsson; Adam Ameur; Ignas Bunikis; Ulf Gyllensten; Bernard Leroy; Magnus Sundström; Patrick Micke; Johan Botling; Thierry Soussi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-24       Impact factor: 11.205

Review 6.  MEG3 noncoding RNA: a tumor suppressor.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  J Mol Endocrinol       Date:  2012-04-02       Impact factor: 5.098

Review 7.  MicroRNAs in the p53 network: micromanagement of tumour suppression.

Authors:  Heiko Hermeking
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

Review 8.  TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.

Authors:  Ashkan Shahbandi; Hoang D Nguyen; James G Jackson
Journal:  Trends Cancer       Date:  2020-02-05

9.  Pathways of Metabolite-Related Damage to a Synthetic p53 Gene Exon 7 Oligonucleotide Using Magnetic Enzyme Bioreactor Beads and LC-MS/MS Sequencing.

Authors:  Spundana Malla; Karteek Kadimisetty; Di Jiang; Dharamainder Choudhary; James F Rusling
Journal:  Biochemistry       Date:  2018-05-23       Impact factor: 3.162

10.  Direct LC-MS/MS Detection of Guanine Oxidations in Exon 7 of the p53 Tumor Suppressor Gene.

Authors:  Di Jiang; Spundana Malla; You-Jun Fu; Dharamainder Choudhary; James F Rusling
Journal:  Anal Chem       Date:  2017-11-22       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.